William Blair reaffirmed their outperform rating on shares of Akari Therapeutics PLC (NASDAQ:AKTX) in a research note issued to investors on Tuesday, July 4th, StockTargetPrices.com reports.
A number of other research analysts also recently commented on the company. Zacks Investment Research downgraded Akari Therapeutics PLC from a hold rating to a sell rating in a research note on Friday, June 30th. Canaccord Genuity reiterated a buy rating and set a $15.00 price target (down previously from $33.00) on shares of Akari Therapeutics PLC in a research note on Monday, June 26th. Finally, Chardan Capital upgraded Akari Therapeutics PLC from a sell rating to a neutral rating and decreased their price target for the stock from $6.50 to $6.00 in a research note on Wednesday, May 31st.
Shares of Akari Therapeutics PLC (NASDAQ:AKTX) opened at 4.63 on Tuesday. The stock’s market cap is $54.52 million. The company has a 50-day moving average of $4.75 and a 200 day moving average of $7.98. Akari Therapeutics PLC has a one year low of $4.11 and a one year high of $22.20.
TRADEMARK VIOLATION NOTICE: This article was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/07/30/akari-therapeutics-plc-nasdaqaktx-rating-reiterated-by-william-blair-updated-updated-updated.html.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.